In ovarian cancer, the expression of TIM-3 in the ascites of malignant ovarian cancer patients correlates with Gal-9 levels, suggesting an impact of this immune checkpoint axis on the immunosuppressive environment of epithelial ovarian cancer and indicating that TIM-3 is a promising target for immunotherapy [107] (Fig. 2). The gene discussed is HAVCR2; the disease is ovarian carcinoma.